Mar 19 |
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
|
Mar 15 |
SELLAS Life Sciences looks to raise $20M in a direct offering
|
Mar 15 |
SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
|
Mar 8 |
SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
|
Mar 1 |
SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
|
Feb 29 |
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
|
Feb 6 |
SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
|
Jan 25 |
SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
|
Jan 11 |
Sellas Life Sciences gains on securing orphan drug status for r/r PTCL treatment
|
Jan 10 |
SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
|